Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation of Lipid Rafts (Detergent-Resistant Microdomains) and Comparison to Extracellular Vesicles (Exosomes).

Methods in molecular biology (Clifton, N.J.)·2020
Same author

Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model.

ASN neuro·2019
Same author

Connecting Exosomes and Connexins.

Cancers·2019
Same author

The cross roles of sphingosine kinase 1/2 and ceramide glucosyltransferase in cell growth and death.

Biochemical and biophysical research communications·2018
Same author

Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells.

Journal of neurochemistry·2016
Same author

Neuronal ceroid lipofuscinosis with DNAJC5/CSPα mutation has PPT1 pathology and exhibit aberrant protein palmitoylation.

Acta neuropathologica·2015

Related Experiment Video

Updated: Mar 15, 2026

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons
10:53

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons

Published on: September 15, 2014

15.8K

Quantum dots and potential therapy for Krabbe's disease.

Glyn Dawson1

  • 1Department of Pediatrics, University of Chicago, Chicago, Illinois. dawg@uchicago.edu.

Journal of Neuroscience Research
|September 18, 2016
PubMed
Summary

Quantum dots (QDs) offer a novel approach for delivering enzymes across the blood-brain barrier to treat Krabbe disease (KD). Positively charged QDs successfully target oligodendrocytes, crucial for KD therapy.

Keywords:
GALCJB577Krabbe's diseaseenzyme replacement therapygloboid cell leukodystrophyhematopoietic stem cell transplantationlysosomal storage diseasequantum dots

More Related Videos

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K
An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons
13:46

An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons

Published on: July 11, 2020

6.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons
10:53

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons

Published on: September 15, 2014

15.8K
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K
An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons
13:46

An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons

Published on: July 11, 2020

6.3K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Nanotechnology

Background:

  • Enzyme replacement and substrate reduction therapies are effective for nonneural lysosomal storage diseases but not Krabbe disease (KD).
  • Current therapies face limitations in reversing pathology and improving outcomes for KD, particularly within the central nervous system (CNS).

Purpose of the Study:

  • To explore novel therapeutic strategies for Krabbe disease (KD) by overcoming the blood-brain barrier (BBB).
  • To investigate the potential of quantum dots (QDs) for targeted enzyme delivery to CNS cells affected by KD.

Main Methods:

  • Utilized 6-nm fluorescent quantum dots (QDs) to deliver a cell-penetrating peptide and β-D-galactocerebrosidase across the BBB.
  • Investigated QD coating charges to direct cargo to specific cell types, focusing on oligodendroglia affected in KD.
  • Assessed the efficacy of a positively charged polyethylene glycol coating for targeting oligodendrocytes.

Main Results:

  • Quantum dots (QDs) successfully delivered enzymes across the blood-brain barrier (BBB), enabling tracking and degradation of accumulated material.
  • QD coating charge influenced cellular uptake, with negative charges targeting neurons and positive charges targeting oligodendrocytes.
  • A polyethylene glycol 600 amino coating demonstrated positive charge-mediated targeting of oligodendrocytes.

Conclusions:

  • Quantum dots (QDs) represent a promising platform for CNS enzyme delivery in Krabbe disease (KD) therapy.
  • Targeting specific glial cells like oligodendroglia with tailored QD coatings is feasible.
  • Further development is needed to overcome hurdles for routine CNS enzyme replacement therapy.